


BDP9066

Chemical Properties

CAS No.:	2226507-04-4
Formula:	C ₂₀ H ₂₄ N ₆
Molecular Weight:	348.44
Appearance:	N/A
Storage:	0-4°C for short term (days to weeks), or -20°C for long term (months).



Biological Description

Description	BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation. BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor. With an IC ₅₀ of 64 nM for MRCK β in SCC12 cells, Ki values of 0.0136 nM and 0.0233 nM for MRCK α/β in house determinations, respectively.
Targets(IC ₅₀)	MRCK β in SCC12 cells: 64 nM MRCK α/β : (ki) 0.0136 nM/0.0233 nM
In vitro	BDP9066 inhibits MLC phosphorylation and blocks SCC12 squamous cell carcinoma motility and invasion[1]. BDP9066 shows antiproliferative effects with greatest activity in hematologic cancer cells.
In vivo	BDP9066 topical application significantly decreases phosphorylated MRCK α S1003 staining and tumor volumes[1].

Solubility Information

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.87 mL	14.35 mL	28.699 mL
5 mM	0.574 mL	2.87 mL	5.74 mL
10 mM	0.287 mL	1.435 mL	2.87 mL
50 mM	0.057 mL	0.287 mL	0.574 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

1. Unbekandt M, et al. Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer. Cancer Res. 2018 Apr 15;78(8):2096-2114.

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street,Wellesley Hills,MA 02481